What is the most likely cause of secondary Raynaud's (Raynaud's phenomenon)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most likely cause of secondary Raynaud's phenomenon is connective tissue disorders, particularly systemic sclerosis (scleroderma) 1. Secondary Raynaud's occurs as a result of an underlying condition, unlike primary Raynaud's which occurs on its own. Other common causes include:

  • Systemic lupus erythematosus
  • Rheumatoid arthritis
  • Sjögren's syndrome
  • Mixed connective tissue disease Certain medications can also trigger secondary Raynaud's, including:
  • Beta-blockers
  • Migraine medications containing ergotamine
  • Some chemotherapy agents
  • Certain over-the-counter cold medications Occupational factors such as repetitive trauma from using vibrating tools or typing can lead to secondary Raynaud's, as can certain blood disorders, thyroid problems, and arterial diseases. When evaluating a patient with suspected secondary Raynaud's, it's essential to look for symptoms of underlying conditions such as skin thickening, joint pain, dry eyes and mouth, or unexplained fatigue, as noted in the management of systemic sclerosis 1. The mechanism typically involves abnormal vasoconstriction of small blood vessels in response to cold or emotional stress, but in secondary Raynaud's, this response is exacerbated by the underlying disease process or external factor, which is a key consideration in the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis 1. Some studies have investigated the efficacy of various interventions in patients with Raynaud's phenomenon, including the use of gloves and heating devices for the hands, avoidance of direct contact with cold surfaces, and a thorough drying of the skin 1. However, the primary focus should be on identifying and managing the underlying condition causing secondary Raynaud's, as this can significantly impact morbidity, mortality, and quality of life 1.

From the Research

Secondary Raynaud's Phenomenon

The most likely cause of secondary Raynaud's phenomenon is an underlying autoimmune connective tissue disease, such as:

  • Systemic sclerosis (SSc) 2, 3, 4
  • Systemic lupus erythematosus (SLE) 5 Other potential causes of secondary Raynaud's phenomenon include:
  • Vaso-occlusive processes 6
  • Endothelium injury by autoantibodies and circulating immune complexes 5
  • Collagen-vascular diseases 5

Key Factors

Key factors that contribute to the development of secondary Raynaud's phenomenon include:

  • Vasospasm within the digital macro- and microvasculature 3
  • Progressive obliterative microangiopathy 3
  • Digital ischemia 3, 6, 4
  • Autoantibodies and circulating immune complexes 5

Diagnosis and Management

Diagnosis and management of secondary Raynaud's phenomenon involve:

  • Comprehensive clinical assessment 2, 4
  • Targeted investigations, such as nailfold capillaroscopy and testing for autoantibodies 2, 4
  • Patient education and lifestyle adaptations 2
  • Pharmacological treatment, including calcium channel blockers, phosphodiesterase type 5 inhibitors, and intravenous prostanoid therapy 6, 4
  • Surgical intervention, such as digital sympathectomy, in severe cases 6, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Raynaud's phenomenon.

British journal of hospital medicine (London, England : 2005), 2019

Research

Raynaud's phenomenon.

Best practice & research. Clinical rheumatology, 2016

Research

[Secondary Raynaud's phenomenon].

Immunitat und Infektion, 1993

Research

Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Current treatment options in cardiovascular medicine, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.